Fruzaqla

Launched

Fruquintinib · Metastatic colorectal cancer (3L+)

VEGFR 1/2/3 inhibitor

Nov 2023 (US), 2024 (EU/JP)

Launch readiness

+2 pts MoM

Regulatory

Trial momentum

-1

Evidence

Access / HTA

Digital momentum

Competitive

Milestone rail

Nov 2023

FDA approval

Jun 2024

EC approval

Sep 2024

Japan approval

2025

NICE recommendation

2027

Earlier-line combination readouts

Clinical trials

ClinicalTrials.gov · Sep 2026

Active P3

Enrollment

68%

Completion in

18mo

Competing programs

Enrollment vs target68%

Publications

PubMed · Sep 2026

Last 12m

Growth

21%

+21%

Top-journal share

24%

Lancet · 3J Clin Oncol · 7ESMO/ASCO · 18Other · 30

Regulatory

openFDA · Sep 2026

Priority Review (completed)FDA approval Nov 2023

4 of 5 tracked milestones complete

HTA / access

HTA decisions / price databases · Sep 2026

NICE

positive

G-BA

positive

HAS

positive

CADTH

positive

PBAC

pending

List price (yr)

$26k

Class median

$22k

above class

Competitor landscape

Public pipelines · Sep 2026

Rival	Status	Launch in	Readiness	Δ efficacy
Lonsurf Taiho / Servier	Marketed SoC	launched	100	0 pts
Regorafenib Bayer	Marketed	launched	96	-4 pts
Lonsurf + bevacizumab Taiho	Marketed (combo)	launched	90	+6 pts

x: efficacy Δ vs SoC · y: access readiness

Risk / opportunity radar

Composite model · Sep 2026

CEO take

Approved US/EU/JP; NICE positive 2025 — access momentum 84/100
FRESCO-2 underpins label; real-world evidence program expanding
3L mCRC niche protected, but competition from trifluridine/tipiracil combos
Digital momentum 71/100 — strongest of the launched cohort
Growth lever: earlier-line combinations under evaluation

Digital signal layer

Multi-source listening · Sep 2026

Search interest index

Google Trends

62idx+4 pts

Congress abstracts 12m

ASCO / ASH / EHA / AAN / ACG

29abstracts+2 new

KOL share of voice

X / LinkedIn / podcasts

24%+1.8 pts

News & PR velocity

Press wires & trade media

18/mo+3 items

Patient community volume

Reddit / Inspire / patient forums

9.8k posts+0.6 k

Community sentiment

NLP over community posts

74/100+1 pt

Payer / formulary chatter

Payer bulletins / guidelines

46idx+5 pts